GLIEMPAFLOZIN MET 5mg/500mg is an advanced oral antidiabetic formulation combining Empagliflozin 5 mg and Metformin Hydrochloride 500 mg. This dual-action therapy is widely prescribed for adults with Type 2 Diabetes Mellitus (T2DM) who require better glycaemic control when diet and lifestyle modifications alone are not sufficient. By bringing together the complementary benefits of an SGLT2 inhibitor (Empagliflozin) and a biguanide (Metformin), the medicine supports stable blood sugar reduction and helps minimise diabetes-related complications.
This combination is especially beneficial for Indian patients with fluctuating sugar levels, obesity concerns, and cardiovascular risks associated with long-standing diabetes. GLIEMPAFLOZIN MET 5mg/500mg offers convenient dosing and improved treatment outcomes for long-term diabetes management.
Uses
GLIEMPAFLOZIN MET 5mg/500mg is clinically used for:
Management of Type 2 Diabetes Mellitus in adults.
Reducing fasting and postprandial (after-meal) blood sugar levels.
Enhancing insulin sensitivity and lowering hepatic glucose production.
Promoting glucose excretion through urine to maintain balanced sugar levels.
Reducing the risk of diabetes-related cardiovascular events, especially in patients with heart-related comorbidities.
Supporting therapy in overweight individuals by assisting in calorie loss through glycosuria.
This combination is not indicated for Type 1 Diabetes or diabetic ketoacidosis.
Benefits
1. Dual Mechanism for Superior Glycaemic Control
Empagliflozin increases glucose elimination through the kidneys, while Metformin decreases glucose production by the liver and improves peripheral insulin response. Together, they help achieve better glycaemic stability.
2. Helps Reduce Body Weight
Empagliflozin promotes calorie loss through urine, which may support weight reduction—an important aspect of diabetes care in many Indian patients.
3. Cardiovascular and Renal Health Support
Studies show that Empagliflozin may help reduce cardiovascular risks and support kidney function in diabetic patients, making this combination beneficial for long-term health.
4. Low Risk of Hypoglycaemia
Unlike sulfonylureas, GLIEMPAFLOZIN MET 5mg/500mg has a minimal risk of causing low blood sugar when used alone.
5. Improved Glycaemic Outcomes
The combination targets multiple pathways, making it effective in reducing HbA1c levels and preventing long-term diabetes complications such as neuropathy, nephropathy, and retinopathy.
Dosage
The recommended dose of GLIEMPAFLOZIN MET 5mg/500mg should be taken once or twice daily, depending on the physician’s advice.
It is usually taken after meals to minimise gastric discomfort.
Swallow the tablet whole with water; do not crush or chew.
Your doctor may adjust the dose depending on:
Blood sugar levels
Age
Kidney function
Treatment response
Never exceed the prescribed dosage without medical supervision.
Side Effects
While generally well-tolerated, some patients may experience:
Common Side Effects
Increased urination
Thirst or dry mouth
Mild urinary tract infections
Nausea, vomiting, or stomach discomfort
Diarrhoea or abdominal pain
Headache or weakness
Less Common but Serious Side Effects
Dehydration
Lactic acidosis (rare but serious with Metformin)
Severe genital infectionsKidney function changes
Hypotension due to fluid loss
If symptoms worsen or do not improve, seek medical advice immediately.
Precautions and Warnings
Not recommended for patients with Type 1 Diabetes or ketoacidosis.
Use cautiously in individuals with kidney or liver impairment.
Patients should maintain adequate hydration to avoid dehydration.
Inform your doctor if you experience recurrent UTIs or genital infections
Avoid alcohol intake, as it may increase the risk of lactic acidosis.
Pregnant or breastfeeding women should use this combination only after medical consultation.
Elderly patients may be at higher risk of dehydration and renal concerns.
Stop the medicine temporarily during major surgeries or severe illness as advised by your doctor.
Conclusion
GLIEMPAFLOZIN MET 5mg/500mg is a reliable and effective antidiabetic combination designed to offer comprehensive glycaemic control for adults with Type 2 Diabetes Mellitus. With the proven actions of Empagliflozin and Metformin Hydrochloride, the medicine helps regulate blood sugar, supports weight management, and provides added cardiovascular and renal benefits. When paired with lifestyle changes such as a balanced diet, regular exercise, and periodic monitoring, this therapy can significantly improve long-term diabetes outcomes for Indian patients.
